Dexcel Pharma

Highly Engaged Employees

Dexcel Pharma, established in 1968, stands as Israel’s largest privately owned pharmaceutical entity. The company specializes in the development, manufacturing, and commercialization of a diverse portfolio, including value-added branded prescription drugs, generics, and over-the-counter (OTC) products. Its primary focus is on oral solid dosage forms, a testament to its specialized manufacturing capabilities. Dexcel Pharma supplies an extensive range of over 85 products, available in more than 175 dosage forms, catering to critical healthcare needs across multiple international markets.

With a significant operational footprint, Dexcel Pharma serves key global markets such as the U.S., U.K., Germany, and Austria, alongside numerous other regions through its established subsidiaries and distribution networks. The company operates across 8 locations and employs a substantial workforce ranging from 1,000 to 5,000 individuals, reflecting its considerable scale and capacity. This robust infrastructure supports its mission to deliver high-quality pharmaceutical solutions worldwide. To understand the human capital driving these operations, consider to Meet Dexcel Pharma's team for insights into their leadership and expertise.

Generating revenue of $405.1M, Dexcel Pharma demonstrates strong market performance within the competitive pharmaceutical and healthcare sectors. Its strategic approach emphasizes value-added branded products alongside essential generics and OTC offerings, ensuring broad market accessibility and therapeutic coverage. The company's commitment to quality and innovation positions it as a key player, contributing significantly to global health outcomes through its comprehensive product lines and extensive market reach.